tirzepatide type 1 diabetes in Adults With Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial @DiabetesCareADA 🔻 −10.3 kg in 12 weeks with tirzepatide vs −0.7 kg with placebo (P<0.0001) 🎯 100% ≥5% Twincretin drug Tirzepatide shows unmatched

These include diseases such as: Cirrhosis (severe scarring of the liver), Hepatitis B or C (viral infections that cause liver inflammation), Non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH)

Clinical Performance: SUSTAIN Trial Results In the SUSTAIN-7 trial (N=1,201), patients with type 2 diabetes randomized to semaglutide 1 mg once weekly lost a mean of 6.5 kg at 40 weeks compared to 3.0 kg with dulaglutide 1.5 mg 2

Statistical analysis and IC 50 /EC 50 determination For all studies, groups were compared to control groups (saline or vehicle)

Many of Saxendas side effects are similar to those that may occur with Zepbound, but the Zepbound alternative can also cause headache, hypoglycemia (low blood sugar), dizziness, increased lipase levels, fever, and gastroenteritis